Personalized chemotherapy for advanced colorectal cancer using organoid testing
Official title: Precision Chemotherapy Based on Organoid for Colorectal CancerPatient-Derived Tumor Organoid Drug Sensitivity for Colorectal Cancer: A Prospective, Multicentre，Randomized, Controlled Trial
Run by Nanfang Hospital, Southern Medical University · NCT05832398 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if personalized chemotherapy based on lab-grown mini tumors can help people with advanced colorectal cancer live longer without their disease getting worse.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 186 (estimated) |
| Sponsor | Nanfang Hospital, Southern Medical University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05832398 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 70 with histologically confirmed stage IV colorectal cancer who are eligible for chemotherapy.
✕Probably not a fit
Patients who refuse chemotherapy or have severe organ damage may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effectiveness of chemotherapy tailored to individual patients with stage IV colorectal cancer based on drug sensitivity tests conducted on patient-derived tumor organoids. The standard treatment involves fluorouracil-based chemotherapy, but its effectiveness is often limited. By using organoids to predict how patients will respond to different chemotherapy regimens, the study aims to validate whether this personalized approach can lead to improved progression-free survival (PFS) outcomes. The trial will involve administering various chemotherapy regimens, including FOLFOX and FOLFIRI, based on the organoid testing results.
Why it matters
Potential benefit: If successful, this approach could significantly improve treatment outcomes for patients with advanced colorectal cancer.
How similar studies have gone: Other studies have shown promise in using organoid models for predicting drug response, suggesting this approach could be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 18 and 70 * Histological confirmed colorectal cancer * Stage IV * American Society of Anesthesiologists (ASA) score I\~III * No contraindication for chemotherapy * No evidence of other malignant tumor Exclusion Criteria: * Refusing chemotherapy * Pregnant or breast-feeding women * Severe organ damage after chemotherapy, surgery or unable to continue to systemic chemotherapy
Where it's running
-
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China Recruiting
Study contacts
- Principal investigator: Jun Yan, M.D., Ph.D — Nanfang Hospital, Southern Medical University
- Study coordinator: Jun Yan, M.D., Ph.D
- Email: yanjunfudan@163.com
- Phone: 086-13825066546
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Knife-assisted full-thickness resection for rectal lesions in a multicenter setting
A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
Liver transplantation for colorectal cancer with liver metastases
This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.
-
LTZ-232: a first-in-human test in advanced colorectal and other solid tumors
A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.